![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
PEARL-IV Trial: Subgroup Analysis of Genotype 1a-infected Patients Treated With Dasabuvir Plus Ombitasvir/ABT-450/r With or Without Ribavirin
|
|
|
Reported by Jules Levin
AASLD 2014 Boston Nov 7-11
David Bernstein1, Yan Luo2, Jacob Lalezari3, David Wyles4, William King5, Naoki Tsai6, Mitchell Davis7, Thomas Sepe8, Jeff rey Fessel9, Marti n King2, Thomas Podsadecki2, Curti s Cooper10
1North Shore University Hospital, Manhasset, New York, United States; 2AbbVie Inc., North Chicago, Illinois, United States; 3Quest Clinical Research, San Francisco, California, United States; 4University of California San Diego, La Jolla, California, United States;
5Trial Management Associates, LLC, Wilmington, North Carolina, United States; 6Queens Medical Center, University of Hawaii, Honolulu, Hawaii, United States; 7Digesti ve Care, South Florida Center of Gastroenterology, Wellington, Florida, United States;
8University Gastroenterology, Providence, Rhode Island, United States; 9Kaiser Permanente, San Francisco, California, United States; 10Ott awa Hospital Research Insti tute, Ott awa, Ontario, Canada
![AASLD1.gif](../images/111314/111314-3/AASLD1.gif)
![AASLD2.gif](../images/111314/111314-3/AASLD2.gif)
![AASLD3.gif](../images/111314/111314-3/AASLD3.gif)
![AASLD4.gif](../images/111314/111314-3/AASLD4.gif)
![AASLD5.gif](../images/111314/111314-3/AASLD5.gif)
![AASLD5.gif](../images/111314/111314-3/AASLD5.gif)
![AASLD6.gif](../images/111314/111314-3/AASLD6.gif)
![AASLD7.gif](../images/111314/111314-3/AASLD7.gif)
![AASLD8.gif](../images/111314/111314-3/AASLD8.gif)
![AASLD9.gif](../images/111314/111314-3/AASLD9.gif)
![AASLD10.gif](../images/111314/111314-3/AASLD10.gif)
![AASLD11.gif](../images/111314/111314-3/AASLD11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|